Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022MMWR. Morbidity and mortality weekly report, 2022-01, Vol.71 (4), p.109-117COPYRIGHT 2022 U.S. Government Printing Office ;Published 2022. This article is a U.S. Government work and is in the public domain in the USA. ;ISSN: 0149-2195 ;EISSN: 1545-861X ;DOI: 10.15585/mmwr.mm7104a1 ;PMID: 35085226Full text available |
|
2 |
Material Type: Article
|
Nationwide comprehensive epidemiological study of rare diseases in Japan using a health insurance claims databaseOrphanet journal of rare diseases, 2022-03, Vol.17 (1), p.140-140, Article 140 [Peer Reviewed Journal]2022. The Author(s). ;COPYRIGHT 2022 BioMed Central Ltd. ;2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2022 ;ISSN: 1750-1172 ;EISSN: 1750-1172 ;DOI: 10.1186/s13023-022-02290-0 ;PMID: 35346288Full text available |
|
3 |
Material Type: Article
|
Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of the Japanese Adverse Drug Event Report DatabaseDrug safety, 2017-11, Vol.40 (11), p.1141-1146 [Peer Reviewed Journal]Springer International Publishing AG 2017 ;Copyright Springer Nature B.V. Nov 2017 ;ISSN: 0114-5916 ;EISSN: 1179-1942 ;DOI: 10.1007/s40264-017-0560-z ;PMID: 28664356Full text available |
|
4 |
Material Type: Article
|
Doxycycline use and adverse pregnancy or neonatal outcomes: A descriptive study using the United States Food and Drug Administration Adverse Event Reporting System databaseHealth science reports, 2022-11, Vol.5 (6), p.e931-n/a [Peer Reviewed Journal]2022 The Authors. published by Wiley Periodicals LLC. ;2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2398-8835 ;EISSN: 2398-8835 ;DOI: 10.1002/hsr2.931Full text available |
|
5 |
Material Type: Article
|
Factors Influencing the Generation of Evidence from Simple Data Held in International Rare Disease Patient RegistriesPharmaceutical medicine, 2020-02, Vol.34 (1), p.31-38 [Peer Reviewed Journal]The Author(s) 2019 ;Copyright Springer Nature B.V. Feb 2020 ;ISSN: 1178-2595 ;EISSN: 1179-1993 ;DOI: 10.1007/s40290-019-00316-w ;PMID: 32048210Full text available |
|
6 |
Material Type: Article
|
Antimicrobial Agent Dosing in InfantsClinical therapeutics, 2016-09, Vol.38 (9), p.1948-1960 [Peer Reviewed Journal]Elsevier HS Journals, Inc. ;2016 Elsevier HS Journals, Inc. ;Copyright © 2016 Elsevier HS Journals, Inc. All rights reserved. ;Copyright Elsevier Limited Sep 2016 ;ISSN: 0149-2918 ;EISSN: 1879-114X ;DOI: 10.1016/j.clinthera.2016.06.017 ;PMID: 27473383Full text available |
|
7 |
Material Type: Article
|
The relationship of psoriasis and melanocytic neviIndian journal of dermatology, 2016-11, Vol.61 (6), p.664-667 [Peer Reviewed Journal]COPYRIGHT 2016 Medknow Publications and Media Pvt. Ltd. ;Copyright Medknow Publications & Media Pvt Ltd Nov-Dec 2016 ;Copyright: © Indian Journal of Dermatology 2016 ;ISSN: 0019-5154 ;EISSN: 1998-3611 ;DOI: 10.4103/0019-5154.193680 ;PMID: 27904187Full text available |
|
8 |
Material Type: Article
|
Tracking the Pharmaceutical Pipeline: Clinical Trials and Global Disease BurdenClinical and translational science, 2014-08, Vol.7 (4), p.297-299 [Peer Reviewed Journal]2014 Wiley Periodicals, Inc. ;Copyright John Wiley & Sons, Inc. Aug 2014 ;ISSN: 1752-8054 ;EISSN: 1752-8062 ;DOI: 10.1111/cts.12163 ;PMID: 24816032Digital Resources/Online E-Resources |
|
9 |
Material Type: Newsletter Article
|
Press Release: Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking AbstractsDow Jones Institutional News, 2024Copyright Dow Jones & Company Inc. May 22, 2024Digital Resources/Online E-Resources |
|
10 |
Material Type: Newsletter Article
|
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking AbstractsNASDAQ OMX's News Release Distribution Channel, 2024GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
11 |
Material Type: Newsletter Article
|
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024NASDAQ OMX's News Release Distribution Channel, 2024GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
12 |
Material Type: Newsletter Article
|
Anvisa approves drug that prevents respiratory virus in babiesCE Noticias Financieras, 2023CE Noticias Financieras English, Latin America - Distributed by ContentEngine LLCDigital Resources/Online E-Resources |
|
13 |
Material Type: Newsletter Article
|
Press Release: Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical ProgramsDow Jones Institutional News, 2021Copyright Dow Jones & Company Inc Mar 12, 2021Digital Resources/Online E-Resources |
|
14 |
Material Type: Newsletter Article
|
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical ProgramsNASDAQ OMX's News Release Distribution Channel, 2021GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
15 |
Material Type: Newsletter Article
|
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)NASDAQ OMX's News Release Distribution Channel, 2024GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
16 |
Material Type: Newsletter Article
|
Crinetics Pharmaceuticals Reports Top-Line Results Including Strong Adrenal Suppression From CRN04894 Phase 1 Study Multiple-Ascending Dose CohortsBenzinga Newswires, 20222020 Benzinga.com - Benzinga does not provide investment advice. All rights reserved.Digital Resources/Online E-Resources |
|
17 |
Material Type: Newsletter Article
|
Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of NeuroendocrinologyNASDAQ OMX's News Release Distribution Channel, 2022GlobeNewswire, Inc.Digital Resources/Online E-Resources |
|
18 |
Material Type: Newsletter Article
|
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital HyperinsulinismNews Bites US - NASDAQ, 2020Copyright News Bites Pty Ltd Sep 22, 2020Digital Resources/Online E-Resources |
|
19 |
Material Type: Newsletter Article
|
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose CohortsNews Bites US - NASDAQ, 2022Copyright News Bites Pty Ltd May 26, 2022Digital Resources/Online E-Resources |
|
20 |
Material Type: Newsletter Article
|
Advancement of gene therapies increases pharmaceutical industry pressure on heel testingCE Noticias Financieras, 2022CE Noticias Financieras English, Latin America - Distributed by ContentEngine LLCDigital Resources/Online E-Resources |